A practical reference on nuclear receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-26. Anything still debated is marked as such rather than presented as settled.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Arsène Charles Ernest Wenger (born 22 October 1949) is a French former football manager and player who has been serving as FIFA's Chief of Global Football Development since 2019. Nicknamed Le Professeur, he is widely regarded as one of the most influential football managers of his generation. Wenger was the manager of Arsenal from 1996 to 2018, becoming the longest-serving and most successful manager in the club's history and the longest-serving manager in the history of the Premier League. Born in Strasbourg and raised in Duttlenheim, Wenger was introduced to football by his father, the manager of the local village team. After a modest playing career as a midfielder, with appearances for clubs including FC Mulhouse and RC Strasbourg, he obtained a manager's diploma in 1981. Wenger began his managerial career at Nancy in 1984 before joining Monaco in 1987. At Monaco, he won the French league title and the Coupe de France in 1991. In 1995, Wenger moved to Japan to manage Nagoya Grampus Eight, where he won both the Emperor's Cup and the Japanese Super Cup. In 1996, Wenger was appointed manager of Arsenal. Initially greeted with scepticism by the English media, he went on to transform the club and English football through innovations in nutrition, training methods, and global scouting. He became the first foreign manager to win a Premier League and FA Cup double in 1998, repeated the feat in 2002, and led Arsenal to an unbeaten league title in 2004. His team later set an English record of 49 consecutive league matches unbeaten.
After the collapse of the Kingdom of Yugoslavia in the April War (1941), the entire country was occupied and partitioned between Axis powers. Central territories of Serbia and the northern region of Banat were occupied by Nazi Germany, that enforced direct control over the Territory of the Military Commander in Serbia, with a puppet Government installed in Belgrade. Southern regions of Metohija and Kosovo were occupied by Fascist Italy and annexed into the Italian Albania. The region of Bačka was annexed by Hungary, while Syrmia was possessed by the Independent State of Croatia. Southeastern parts of Serbia were occupied by Bulgaria. At the beginning of the occupation, there were two resistance movements: Chetniks and Partisans. They had conflicting ideological and political programs, with Chetniks abandoning initial joint resistance efforts alongside Partisans by the end of the Uprising in Serbia, switching instead to extensive collaboration with Axis forces. Partisans advocated transformation of Yugoslavia into a federation, with Serbia becoming one of its federal units. In the autumn of 1941, first provisional institutions were established by partisans in some liberated territories, headed by the Main National Liberation Committee for Serbia. It was seated in Užice, and thus the movement became known as the Republic of Užice. However, the German offensive crushed this proto-state in December of the same year. After that, main partisan forces moved to Bosnia.
== Mechanical bonding and chemical reactivity == The introduction of a mechanical bond alters the chemistry of the sub components of rotaxanes and catenanes. Steric hindrance of reactive functionalities is increased and the strength of non-covalent interactions between the components are altered.
PRRT radiopharmaceuticals are constructed with three components; the radionuclide, chelator, and somatostatin analogue (peptide). The radionuclide delivers the actual therapeutic effect (or emission, such as photons, for imaging). The chelator is the essential link between the radionuclide and peptide. For 177Lu and 90Y this is typically DOTA (tetracarboxylic acid, and its variants) and DTPA (pentetic acid) for 111In. Other chelators known as NOTA (triazacyclononane triacetic acid) and HYNIC (hydrazinonicotinamide) have also been experimented with, albeit more for imaging applications. The somatostatin analogue affects biodistribution of the radionuclide, and therefore how effectively any treatment effect can be targeted. Changes affect which somatostatin receptor is most strongly targeted. For example, DOTA-lanreotide (DOTALAN) has a lower affinity for receptor 2 and a higher affinity for receptor 5 compared to DOTA-octreotide (DOTATOC).
Sources: en.wikipedia.org
=== Testosterone === Men with low levels of testosterone can experience ED. Taking testosterone may help maintain an erection. Males with type 2 diabetes are twice as likely to have lower levels of testosterone, and are three times more likely to experience ED than non-diabetic men.
=== „Sozusagen Paris“ (2016) === „Sozusagen Paris“' (Paris, So to Speak) constitutes a sequel to the previous novel: after a public reading from „Love Writ Large“, the first-person narrator is approached by his childhood sweetheart, who is now the mayor of a small town. This sequel describes the first encounter between the two characters after thirty years, which lasts from the moment of their reunion after the public reading until the next morning. Overall, the text complements its predecessor: whereas the former dealt with the ecstasy of first love, the latter focuses on long-term love, specifically in light of Jutta's 23-year marriage. Whereas „Love Writ Large“ was told from the man's perspective, the nighttime conversation in Paris, So to Speak is shaped by the woman’s point of view —for the first time in Kermani's work, a female voice is at the center of the text. Like „Love Writ Large, Paris So to Speak“ also aims at a supra-individual exploration of love, but it is anchored differently: instead of early Islamic mysticism, it’s the French marriage novels of the nineteenth century up to Marcel Proust which serve as a foil here for modern love. This shifts the reflection on love from a general anthropological to a historical perspective. In particular, the important role of their children to the couple's life, lifestyle, and emotional stability serves to emphasize distinctions from older marriage novels and to highlight specifics of love and cohabitation in the 21st century.
The ELISA template, commonly used for performing immunoassays and other enzyme-based biochemical assays, has been adapted for use with the DMF platform for the detection of analytes such as IgE and IgG. In one example, a series of bioassays were conducted to establish the quantification capabilities of DMF devices, including an ELISA-based immunoassay for the detection of IgE. Superparamagnetic nanoparticles were immobilized with anti-IgE antibodies and fluorescently labeled aptamers to quantify IgE using an ELISA template. Similarly, for the detection of IgG, IgG can be immobilized onto a DMF chip, conjugated with horseradish-peroxidase (HRP)-labeled IgG, and then quantified through measurement of the color change associated with product formation of the reaction between HRP and tetramethylbenzidine. To further expand the capabilities and applications of DMF immunoassays beyond colorimetric detection (i.e., ELISA, magnetic bead-based assays), electrochemical detection tools (e.g., microelectrodes) have been incorporated into DMF chips for the detection of analytes such as TSH and rubella virus. For example, Rackus et al. integrated microelectrodes onto a DMF chip surface and substituted a previously reported chemiluminescent IgG immunoassay with an electroactive species, enabling detection of rubella virus. They coated magnetic beads with rubella virus, anti-rubella IgG, and anti-human IgG coupled with alkaline phosphatase, which in turn catalyzed an electron transfer reaction that was detected by the on-chip microelectrodes.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.